Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer technology behind Novartis’…
Bristol Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical companies have spent some $10 billion on radiopharmaceuticals acquisitions and partnerships over the past year.Radiopharmaceuticals are currently available for some neuroendocrine tumors and prostate cancer. They could one day be used for numerous cancers.and other pharmaceutical companies have spent some $10 billion on deals to acquire or work with radiopharmaceuticals makers.
66-year-old billionaire says there's 1 trait it takes to succeed: ‘It doesn't matter how much experience they have' Pharmaceutical companies proved they could manage complex, time-sensitive drugs like CAR-T for blood cancers or gene therapies for rare diseases. Then Novartis showed those strategies could be applied in radiopharmaceuticals.
Manufacturing was also a key component in Bristol Myers Squibb's $4.1 billion acquisition of RayzeBio, said Ben Hickey, RayzeBio's president. At the time of the acquisition, RayzeBio was nearing completion of a factory in Indiana and had secured its own supply of radioactive material needed to develop the experimental drugs in its pipeline.
It can take a few weeks from prescribing a radiopharmaceutical to administering one. For Pluvicto, patients come in once every six weeks for up to six treatments.Ronald Coy knows how important it is to make it in for his appointments. Coy, a retired firefighter who's been battling prostate cancer since 2015, drives more than an hour through upstate New York to receive Pluvicto at Bassett.
At this point, it's still an if. The field is in its early days, executives say, and the promise of radiopharmaceuticals beyond the current cancers they treat still needs to be proven.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The forgotten pharma stocks left in the dust by Eli-Lilly could be primed for a comebackKatie Stockton breaks down the charts in Bristol-Myers, J&J and Pfizer.
Read more »
Drugmakers say obesity medicine shortages are easing, but patients struggle to fill prescriptionsThe drug companies behind blockbuster weight loss and diabetes treatments have signaled that supply problems could soon be over, but many patients still have trouble getting the medicines.
Read more »
Drugmakers say obesity medicine shortages are easing, but patients struggle to fill prescriptionsThe drug companies behind blockbuster weight loss and diabetes treatments have signaled that supply problems could soon be over, but many patients still have trouble getting the medicines.
Read more »
Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-OldsScience and Technology News and Videos
Read more »
Indonesia court fines drugmakers for toxic cough syrup that killed childrenThe court ordered the companies to pay 20 families who brought the suit compensation of 50 million rupiah ($3,217) for children who died and 60 million ($3,850) rupiah for children who were injured.
Read more »
Drugmakers at fault over toxic cough syrup, Indonesia court findsAn Indonesian court ordered two local companies to pay up to 60 million rupiah ($3,850) to each family whose children died of an acute kidney injury or were seriously injured after consuming toxic cough syrup.
Read more »